

Liwei Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/37039/publications.pdf>

Version: 2024-02-01

21
papers

1,225
citations

686830

13
h-index

713013

21
g-index

22
all docs

22
docs citations

22
times ranked

1432
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of immunogenic cell death and its relevance for cancer therapy. <i>Cell Death and Disease</i> , 2020, 11, 1013.	2.7	466
2	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
3	eIF2 β phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , 2018, 25, 1375-1393.	5.0	162
4	Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. <i>EMBO Journal</i> , 2018, 37, .	3.5	81
5	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. <i>Molecular Cell</i> , 2020, 77, 748-760.e9.	4.5	77
6	Identification of pharmacological agents that induce HMGB1 release. <i>Scientific Reports</i> , 2017, 7, 14915.	1.6	37
7	Crizotinib â€“ a tyrosine kinase inhibitor that stimulates immunogenic cell death. <i>Oncolmunology</i> , 2019, 8, e1596652.	2.1	25
8	PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. <i>Oncolmunology</i> , 2022, 11, .	2.1	25
9	Identification of pharmacological inhibitors of conventional protein secretion. <i>Scientific Reports</i> , 2018, 8, 14966.	1.6	21
10	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. <i>Cell Death and Disease</i> , 2021, 12, 6.	2.7	21
11	Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis. <i>Oncolmunology</i> , 2020, 9, 1792037.	2.1	17
12	Quantitation of calreticulin exposure associated with immunogenic cell death. <i>Methods in Enzymology</i> , 2020, 632, 1-13.	0.4	16
13	Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Golgi apparatus. <i>Oncotarget</i> , 2018, 9, 31169-31170.	0.8	15
14	Epigenetic anticancer agents cause HMGB1 release <i>in vivo</i> . <i>Oncolmunology</i> , 2018, 7, e1431090.	2.1	12
15	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. <i>Oncolmunology</i> , 2019, 8, 1606665.	2.1	12
16	Secreted calreticulin mutants subvert anticancer immunosurveillance. <i>Oncolmunology</i> , 2020, 9, 1708126.	2.1	11
17	Methods for measuring HMGB1 release during immunogenic cell death. <i>Methods in Enzymology</i> , 2019, 629, 177-193.	0.4	7
18	Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score. <i>Cancer Management and Research</i> , 2021, Volume 13, 6473-6487.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. <i>Oncolimmunology</i> , 2020, 9, 1789284.	2.1	4
20	Assessment of type I interferon responses as a feature of immunogenic cell death. <i>Methods in Cell Biology</i> , 2022, , 135-143.	0.5	4
21	Assessment of immunological memory formation in vivo. <i>Methods in Cell Biology</i> , 2022, , .	0.5	0